Sotac Pharmaceuticals (NSE:SOTAC) Research & Development: ₹0.0 Mil (TTM As of Sep. 2025)


NSE:SOTAC Sotac Pharmaceuticals Ltd NSE:SOTAC
53 GF Score
Price ₹105.00
GF Value ₹110.01
Valuation Fairly Valued
! 6 Warning Signs
View Full Analysis

What is Sotac Pharmaceuticals Research & Development?

Sotac Pharmaceuticals NSE:SOTAC 53 Research & Development is ₹0.0 Mil as of Sep. 2025. GuruFocus rates NSE:SOTAC with a GF Score™ of 53/100 and a GF Value™ of ₹110.01 (Fairly Valued). The stock has 6 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Sotac Pharmaceuticals's Research & Development for the six months ended in Sep. 2025 was ₹0.0 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Sep. 2025 was ₹0.0 Mil.

Sotac Pharmaceuticals  (NSE:SOTAC) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Sotac Pharmaceuticals Research & Development Related Terms

Sotac Pharmaceuticals Research & Development Historical Data

* Premium members only.

The historical data trend for Sotac Pharmaceuticals's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sotac Pharmaceuticals Research & Development Chart

Sotac Pharmaceuticals Annual Data
Trend Mar20 Mar21 Mar22 Mar23 Mar24 Mar25
Research & Development
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Sotac Pharmaceuticals Semi-Annual Data
Mar20 Mar21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
NSE:SOTAC
53GF Score
Sotac Pharmaceuticals Ltd NSE:SOTAC
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sotac Pharmaceuticals Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Sep. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was ₹0.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of ₹0.0 Mil mean?
Sotac Pharmaceuticals (NSE:SOTAC) has a Research & Development of ₹0.0 Mil as of Sep. 2025. Research and development expense is the total cost for research and development activities. View historical data on Sotac Pharmaceuticals and its competitors.
Is Sotac Pharmaceuticals' Research & Development too high?
Sotac Pharmaceuticals' current Research & Development is ₹0.0 Mil. Overall, Sotac Pharmaceuticals has a GF Score™ of 53/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Sotac Pharmaceuticals' Research & Development compare to ZTS and UTHR?
Sotac Pharmaceuticals' Research & Development of ₹0.0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Drug Manufacturers company?
A good Research & Development depends on the Drug Manufacturers industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Sotac Pharmaceuticals and its competitors. Sotac Pharmaceuticals's current Research & Development is ₹0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sotac Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Sotac Pharmaceuticals (NSE:SOTAC) is currently considered Fairly Valued. The stock's GF Value™ is ₹110.01, compared to a current price of ₹105.00 — trading 4.6% below its estimated fair value. The current Research & Development is ₹0.0 Mil. Sotac Pharmaceuticals' overall GF Score™ is 53/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Sotac Pharmaceuticals (NSE:SOTAC), the current Research & Development is ₹0.0 Mil as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sotac Pharmaceuticals (NSE:SOTAC) Overvalued in 2026?

Based on GuruFocus' analysis, Sotac Pharmaceuticals stock appears to be undervalued. The current stock price of ₹105.00 is trading 4.6% below its estimated GF Value™ of ₹110.01. GuruFocus considers Sotac Pharmaceuticals to be Fairly Valued.

Key valuation signals for NSE:SOTAC:

  • Research & Development: ₹0.0 Mil
  • GF Value™: ₹110.01 vs. price of ₹105.00 (4.6% below fair value)
  • GF Score™: 53/100 with 6 warning signs

No single metric tells the full story. See the NSE:SOTAC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sotac Pharmaceuticals Business Description

Address Plot No. PF-21 & PF-22/A, Charal Industrial Estate, Sanand GIDC-II, Sanand, Ahmedabad, GJ, IND, 382110
Sotac Pharmaceuticals Ltd operates chiefly in pharmaceutical manufacturing, serving a broad range of therapeutic segments including anti-diabetic, anti-psychotic, vitamins and minerals, anti-cold, anti-allergic, derma products, antacids, anti-ulcerants, cardiac, analgesic, anti-bacterial, anti-fungal, and more. The company manufactures tablets, capsules, syrups, and external preparations under contract manufacturing and loan licensing agreements, for domestic and international markets. Its clients include notable pharmaceutical marketers such as Cadila Pharma and Viatris. Revenue is distributed between domestic pharmaceutical product sales and international exports, supporting scalable growth across geographies.
53GF Score

Get the complete analysis for NSE:SOTAC

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹105.00
Price
₹110.01
GF Value